BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™

Core Insights - Highmark Blue Cross Blue Shield has released a draft medical policy expanding coverage for adolescent and adult patients with major depressive disorder (MDD) to include BrainsWay's accelerated Deep TMS™ protocol [1][2] - The new policy is expected to take effect in February 2026, following an open comment period, and will cover BrainsWay's accelerated SWIFT™ protocol, which involves a total of 38 treatment sessions [2] - BrainsWay's accelerated depression protocol for Deep TMS received FDA clearance in September 2025, demonstrating an 87.8% response rate and a 78.0% remission rate in clinical trials [4] Company Overview - BrainsWay is a leader in noninvasive neurostimulation treatments for mental health disorders, with a proprietary Deep TMS™ platform technology [5] - The company has obtained three FDA-cleared indications for its treatments, including major depressive disorder, obsessive-compulsive disorder, and smoking addiction [5] - BrainsWay is committed to advancing neuroscience and increasing global awareness and access to Deep TMS [5]